• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Natera, Inc. - Common Stock (NQ:NTRA)

    198.93 +5.71 (+2.96%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Natera, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Natera Provides Update on Patent Litigation with NeoGenomics
    From Natera, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga
    Why Natera (NTRA) Stock Is Up Today
    Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 3% in the afternoon session after the company announced its Signatera molecular residual disease test was selected for a Phase III... 
    Via StockStory
    Topics Earnings
    Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
    From Natera, Inc.
    Via Business Wire
    5 Analysts Have This To Say About Natera
     
    Via Benzinga
    How Is The Market Feeling About Natera?
     
    Via Benzinga
    2 Cash-Heavy Stocks Worth Investigating and 1 We Ignore
    A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
    Via StockStory
    Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
    From Natera, Inc.
    Via Business Wire
    Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
    From Natera, Inc.
    Via Business Wire
    Earnings Scheduled For August 7, 2025
     
    Via Benzinga
    How Do Investors Really Feel About Natera?
     
    Via Benzinga
    Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
    From Natera, Inc.
    Via Business Wire
    1 Healthcare Stock to Own for Decades and 2 We Find Risky
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
    Via StockStory
    Topics Retirement Stocks
    IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
    From Natera, Inc.
    Via Business Wire
    $1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
     
    Via Benzinga
    NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures
    Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue... 
    Via StockStory
    Topics Artificial Intelligence
    2 Mid-Cap Stocks on Our Watchlist and 1 We Brush Off
    Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
    Via StockStory
    1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Turn Down
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
    Via StockStory
    Tech Stocks Eye Record Highs As Magnificent Seven Top $19.5 Trillion: What's Moving Markets Friday?
    Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and... 
    Via Benzinga
    Why Are Natera (NTRA) Shares Soaring Today
    Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 11.6% in the morning session after it reported strong second-quarter 2025 financial results, including a significant revenue beat and... 
    Via StockStory
    Topics Earnings World Trade
    SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday
     
    Via Benzinga
    Topics Artificial Intelligence
    Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6%
    Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue... 
    Via StockStory
    Natera NTRA Q2 2025 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Natera (NTRA) Q2 Revenue Jumps 32%
    Via The Motley Fool
    12 Health Care Stocks Moving In Thursday's After-Market Session
     
    Via Benzinga
    Natera Reports Second Quarter 2025 Financial Results
    From Natera, Inc.
    Via Business Wire
    Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
    From Natera, Inc.
    Via Business Wire
    What To Expect From Natera’s (NTRA) Q2 Earnings
    Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s what you need to know. 
    Via StockStory
    Topics Artificial Intelligence
    Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
    From Natera, Inc.
    Via Business Wire
    Natera to Report Its Second Quarter Results on August 7, 2025
    From Natera, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.